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Abstract 
The present study examined the impact of the menstrual cycle and oral 
contraceptive use on performance of high intensity intermittent running in the 
heat [31.0 (0.2) oC; 23.1 (0.9) % RH]. Seven normally menstruating women 
(NM) and 8 oral contraceptive (OC) users participated in the study. Two trials 
were undertaken near the predicted mid-point of the follicular (FT) and luteal 
(LT) phases of the menstrual cycle and the equivalent days for the oral 
contraceptive users. Basal serum progesterone concentrations were higher during 
the LT for the NM group [FT: 2.42 (0.28) vs. LT: 25.96 (11.28) nmol.l-1; 
P<0.05], but were not different for the OC [1-14: 2.79 (0.38) vs. 15-28: 2.61 
(0.32) nmol.l-1]. There were no differences in distance run between menstrual 
cycle phases or between the normally menstruating and oral contraceptive groups 
[NM FT: 6257 (1401) vs. LT: 5861 (1035) m]. However the OC ran further in 
the days 15-28 compared to days 1-14 [OC 1-14: 5481 (612) vs 15-28: 6615 
(893) m, P<0.05]. For the NM, rectal temperature, perceived exertion, estimated 
SR, serum growth hormone, plasma lactate, ammonia and glucose did not differ 
between phases of the menstrual cycle. For the OC, heart rate, perceived 
exertion, sweat rate, plasma lactate and ammonia did not differ between days 1-
14 of oral contraceptive use and days 15-28. However rectal temperature was 
higher (P<0.05) and growth hormone tended to be higher (P=0.05) during days 
15-28, while plasma glucose was lower (P<0.05). These results demonstrate that 
for unacclimatised games players the performance of intermittent, high intensity 
shuttle running in the heat is unaffected by menstrual cycle phase but is 
influenced by oral contraceptive use.  
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Introduction 
Cyclic variations in deep body temperature during the menstrual cycle may alter 
thermoregulatory responses, and thus possibly performance, when exercising in 
the heat. In moderate environmental conditions the performance of continuous 
(90% V
.
O2 max) and progressive high intensity running was unaffected by 
menstrual cycle phase (Lebrun et al. 1995; Lynch and Nimmo 1998). However, 
very few studies (Horvath and Drinkwater 1982; Carpenter and Nunneley 1988; 
Stephenson and Kolka 1988) have examined performance in the follicular and 
luteal phases of the menstrual cycle in the heat, despite numerous international 
competitions being organised in hot climates. From the studies that have been 
undertaken it was concluded that cycling and walking performance were 
unaffected by menstrual phase. In addition, it has been shown that during sub-
maximal cycling in the heat for acclimatised subjects, deep body temperature 
may be higher during the luteal compared with the follicular phase (Carpenter 
and Nunneley 1988). For unacclimatised subjects reports are controversial, with 
deep body temperature reported to be higher (Stephenson and Kolka 1988) or 
unaffected by menstrual phase (Wells and Horvath 1974; Horvath and 
Drinkwater 1982).  
 
Furthermore, no study has examined the metabolic and hormonal responses to 
exercise in the heat during the follicular and luteal phases of the cycle. In 
moderate environmental conditions, for sub-maximal cycling and treadmill 
running, blood glucose was similar in the follicular and luteal phases (Bonen et 
al. 1983; Kanaley et al. 1992; Zderic et al. 2001) whereas, for moderate intensity 
cycling and running, blood glucose has been shown to be lower (Lavoie et al. 
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1987) or higher during the luteal phase (Galliven et al. 1997; Zderic et al. 2001). 
Again in moderate environmental conditions, growth hormone responses to 
cycling and treadmill walking were higher during the luteal and ovulatory phases 
of the cycle compared with the follicular phase (Bonen et al. 1983; Hornum et al. 
1997; Zderic et al. 2001). High growth hormone concentrations have been 
associated with the high estrogen concentrations during the luteal and ovulatory 
phases (Hornum et al. 1997). 
 
Many women mask their normal cyclical hormonal changes during the menstrual 
cycle by taking oral contraceptives. However, only two research groups have 
investigated the responses of oral contraceptive users to exercise in the heat 
(Martin and Buono 1997; Stachenfeld et al. 2000). During prolonged moderate 
cycling when taking oral contraceptives, there was a higher heart rate and rectal 
temperature response compared with the same exercise during a contraceptive 
free week (Martin and Buono 1997). Furthermore, again during cycling, when 
women were taking a progestin only contraceptive, oesophageal temperature and 
sweating threshold were higher than when the women were taking a combined 
estrogen and progestin contraceptive (Stachenfeld et al. 2000). In moderate 
environmental conditions during moderate and high intensity treadmill exercise, 
oral contraceptive users had higher growth hormone and lower glucose 
concentrations than eumennorheic women (Bonen et al. 1991; Bemben et al. 
1992). However, no study has examined the performance of oral contraceptive 
users throughout the substitutive therapy cycle in moderate or hot environmental 
conditions. 
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A high deep body temperature has been suggested to be a limiting factor in 
exercise performance in the heat (Nielsen et al. 1990, 1993; Gonzalez-Alonso et 
al. 1999). If during the luteal phase or taking oral contraceptives, a higher deep 
body temperature is observed during exercise, this may decrease the time to 
exhaustion.  
 
Therefore, the purpose of the present study was to test the hypothesis that the 
performance of high intensity, intermittent running exercise in the heat is 
unaffected during the menstrual cycle, or by the use of oral contraceptives. In 
addition, the responses of the eumennorheic women during the normal menstrual 
cycle were compared with those of monophasic oral contraceptive users, across a 
substitutive cycle, before day 14 and after day 14, since the performance, 
hormonal and metabolic responses have not been studied to date. 
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Methods 
Participants 
Fifteen well-trained female games players volunteered for the study, seven of 
whom had normal menstrual cycles (NM) lasting between 24 and 30 days, and 
eight who had been taking monophasic oral contraceptives (OC) for a mean (SE) 
of 22 (6) months. The age, mass and height of the NM and OC groups was 20.3 
(0.3) and 20.2 (0.4) years, 62.1 (2.3) and 59.8 (1.1) kg and 168.4 (2.0) and 165.6 
(1.9) cm respectively. The estimated V
.
O2 max for the NM group was 51.1 (0.7) 
ml.kg-1.min-1 and for the OC group was 50.3 (1.6) ml.kg-1.min-1. All subjects 
gave their written informed consent and the Loughborough University Ethical 
Committee approved the study. The oral contraceptives taken by the participants 
in the OC group are described in Table 1. 
Table 1 
Terminology 
The group with normal menstrual cycles will be referred to as NM and the oral 
contraceptive users OC. For the normal menstruating group the follicular trial 
will be abbreviated to FT and the luteal trial to LT. Monophasic oral 
contraceptive users do not have follicular and luteal phases per se, thus first 14 
days of the oral contraceptive cycle will be termed days 1-14 and the second 14 
day period as days 15-28 of oral contraceptive use.  
 
Experimental design 
Subjects performed the Loughborough Intermittent Shuttle Test (LIST; Nicholas 
et al. 1995, 2000) in hot environmental conditions (31.0 (0.2) oC, 23.1 (0.9) % 
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RH). The mean difference ± 95% limits of agreement for the LIST is –0.7 ± 5.6 
min. For the NM, two main trials were completed during the follicular phase, ~7 
days after the onset of menstruation and in the luteal phase, ~ day 21. For the 
OC, two trials were completed at the equivalent days. The order of trials was 
randomly assigned and 14 days elapsed between the follicular (FT) and luteal 
trials (LT) for the normal menstruating (NM) women and between trials for the 
oral contraceptive (OC) users. Subjects exercised over a 20 m distance and 
repeated a walk, sprint, cruise (~95% V
.
O2 max) and jog (~55% V
.
O2 max) pattern 
of exercise until 11 sprints had been completed. The 11 sprints took 
approximately 15 min and were followed by a 3 min rest period. This series of 
activities constituted 1 set of the LIST. This pattern was repeated until 
exhaustion, or rectal temperature reached 39.5oC.  
 
Preliminary measurements 
Maximal oxygen uptake (V
.
O2 max) was estimated using the progressive 
multistage fitness test (Ramsbottom et al. 1988). From this estimate of V
.
O2 max, 
running speeds to elicit 95 and 55% V
.
O2 max were determined. Volunteers were 
then familiarised with the LIST at ~30oC for 2 sets or ~30 min.  
 
Main trials 
Subjects reported to the laboratory at least 12 h after their last meal. In the 2 days 
prior to each trial subjects were encouraged to consume the same diet. All 
experiments were arranged so that each individual ran at the same time of day for 
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both trials to control for circadian influences. Nude body mass was recorded and 
a 45 mm cannula was then inserted into a forearm vein of the subject under local 
anaesthetic (Lignocaine hydrochloride 1% w/v). The cannula was kept patent 
with saline solution (Sodium choloride 0.9%). A rectal probe (Edale Instruments 
Ltd.) was inserted to a depth of 10 cm beyond the anal sphincter.  
 
Fifteen minutes after cannulation, during which time subjects remained standing, 
a resting blood sample was collected. Subjects then moved into the gymnasium 
and a resting rectal temperature was recorded. A standardised warm-up of ~15 
min was performed which consisted of jogging, stretching and faster pace 
running. During the warm up and throughout the exercise period subjects were 
encouraged to drink water to ensure adequate hydration levels.  
 
During the sprints subjects were verbally encouraged to perform maximally. 
Sprint times over 15 m were measured using 2 infra-red photo electric cells 
connected to the microcomputer. Heart rate was continuously monitored 
throughout each test using short range telemetry (Sport TesterTM, Polar Electro 
Fitness Technology). Rating of perceived exertion was recorded prior to the 11th 
sprint in each exercise set using the Borg scale (1962). A 10 ml blood sample 
was collected from each subject between the sets of exercise and at exhaustion. 
Rectal temperatures were measured during the 4th and 8th cycle of each set and in 
the 3 min blood sampling period between sets of LIST. When rectal temperatures 
were measured subjects were stationary for 40 m of the 60 m walk in that cycle. 
 
At exhaustion, after the participant had stopped sweating and wiped any excess 
8 
sweat off the skin, nude body mass was again recorded. Sweat rates were 
estimated from pre- and post-exercise nude body mass measurements correcting 
for fluid intake. It was assumed that 1 litre of water was equivalent to 1kg 
 
Blood sampling and analyses 
Five ml of blood was dispensed into an EDTA tube and aliquots from the venous 
sample were used for determination of haematocrit and haemoglobin 
concentration (by microcentrifugation and the cyanmethaemoglobin method 
[Boehringer Mannheim UK] respectively). Changes in plasma volume (%) were 
estimated using the method of Dill and Costill (1974). One ml of blood was 
dispensed immediately into a calcium-heparin tube, centrifuged for 3 min at 
13,000 rev.min-1 (11,337 g) and the plasma frozen at -70oC. Ammonia 
concentration was determined within 24 h using a commercially available kit 
(Sigma Diagnostics). The remaining blood was centrifuged for 15 min at 6000 
rev.min-1 (2415 g) at ~3oC. The resulting plasma was then stored at -20oC for 
subsequent determination of lactate and glucose using fully automated 
colorimetric instrumentation (Cobas Mira, Roche Products Ltd.).  
 
Five ml of blood were also dispensed into a serum tube for determination of 
progesterone and growth hormone concentration by using a commercially 
available radioimmunoassay kits (Diagnostic Products Corporation). The 
progesterone assay has a sensitivity of 0.06 nmol.l-1, an intra-assay coefficient of 
variation (cv) of 2.7-8.8% and an inter-assay cv of 3.9-9.7%. The growth 
hormone assay has a sensitivity of 1.8 mIU.l-1, an intra-assay cv of 1.5-5.9% and 
an inter-assay cv of 3.4-8.3%.  
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 Statistical analyses 
Statistical analyses were undertaken on the NM and OC groups independently to 
allow comparisons between trials. The physiological and blood responses to the 
performance of the LIST were analysed using a two-way analysis of variance 
(ANOVA; trial x time) with repeated measures on one factor (time). Significant 
differences between means were identified using a Tukey post-hoc test.  
Environmental temperatures, distance covered during the LIST, body mass and 
plasma volume responses during the main trials were analysed using a students t-
test. Comparisons between groups and trials were also undertaken. The 
physiological and blood responses to the performance of the LIST were analysed 
using a three-way analysis of variance (ANOVA; group x trial x time) with 
repeated measures on two factors (trial x time). Environmental temperatures, 
distance covered during the LIST, body mass and plasma volume responses 
during the main trials were analysed using a two-way ANOVA (group x trial) 
with repeated measures on one factor (trial). Significant differences between 
means were identified using a Scheffè post-hoc test. Data are presented as means 
(SE) and are based on a subject population of 7 NM and 8 OC unless otherwise 
stated.  
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Results 
Performance  
The distance run during the Loughborough Intermittent Shuttle Test (LIST) was 
not different between groups, all cycle considered [NM: 6059 (896) vs. OC: 6048 
(543) m]. It did not differ either when comparing the luteal and follicular phases 
of the menstrual cycle [FT: 6257 (1401) vs. LT: 5861 (1035) m]. In contrast, the 
oral contraceptive group ran further during days 15-28 [1-14: 5481 (612) vs 15-
28: 6615 (893) m, P<0.05). Maximal 15 m sprint performance did not differ 
between groups and the decline in performance was similar both between groups 
and between trials (main effect time P<0.01, Fig. 1). 
Fig. 1 
Rectal temperature 
The resting rectal temperatures tended to be higher prior to the LT than the FT, 
[Rest, FT: 37.1 (0.1) vs. LT: 37.2 (0.1) oC, n.s., Table 2a] and was higher for the 
OC during days 15-28 than 1-14 [1-14: 37.3 (0.1) vs 15-28: 37.4 (0.0), P<0.05, 
Table 2b]. Rectal temperature increased during exercise but was not different 
between the FT and LT [main effect time P<0.01, Table 2a] and increased at a 
similar rate [FT: 3.36 (0.50) vs LT: 3.38 (0.54) oC.h-1].  For the OC rectal 
temperature increased throughout the exercise period [main effect time P<0.01] 
and was higher during days 15-28 [main effect trial P<0.01, Table 2b]. The rate 
of rise of rectal temperature for the OC was higher during days 1-14 [1-14: 2.78 
(0.35) vs 15-28: 2.40 (0.31) oC.h-1, P<0.05]. Resting rectal temperature was 
higher for the OC than the NM being 37.4 (0.1) oC and 37.2 (0.1) oC respectively 
(P<0.05). The difference observed at rest between the OC and NM was not 
maintained after the onset of exercise. The rate of rise of rectal temperature 
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showed no differences between the two groups [NM: 3.4 (0.4) vs. 2.6 (0.2) oC.h-
1].  
Table 2 
Heart rate and rating of perceived exertion 
Heart rate increased with exercise time for both the NM and OC groups (main 
effect time P<0.01). Heart rate was unaltered by menstrual phase or oral 
contraceptive status and did not differ between the groups. Table 3 shows that 
rating of perceived exertion (RPE) increased with exercise time (P<0.01) and 
was not different between menstrual phase or oral contraceptive use.  
Table 3 
Body mass, fluid consumption and estimated sweat rate 
Body mass was well maintained by both groups during the two trials. The change 
in body mass as a percentage of basal body mass for the NM was –0.13 (0.24) 
and 0.06 (0.16) % for the FT and LT respectively and for the OC was –0.51 
(0.10) and –0.25 (0.22) %. Ad libitum fluid consumption was not different 
between the FT and LT [NM FT: 19.6  (4.4) vs. LT: 17.1 (2.6) ml.kg-1.h-1] or 
between trials for the OC [OC 1-14: 16.1 (1.65) vs. 15-28: 16.8 (2.6) ml.kg-1.h-1]. 
Similarly there were no differences in fluid consumption between groups. 
Estimated sweat rate was not different between menstrual phase [NM FT:1.30 
(0.07) vs LT: 0.99 (0.15) l.h-1] or days 1-14 and 15-28 for the OC [OC 1-14: 1.41 
(0.13) vs 15-28: 1.27 (0.09) l.h-1]. There was no difference between the two 
groups.  
 
Hormonal responses 
Resting serum progesterone concentrations for the NM were greater for the LT 
than the FT [P<0.05; FT: 2.42 (0.28) vs. LT: 25.96 (11.28; range 6.7-72.8) 
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nmol.l-1], confirming the normality of the menstrual cycle and ovulation for this 
group. In contrast, progesterone concentrations were the same throughout the 
cycle for the OC group [1-14: 2.79 (0.38) vs. 15-28: 2.61 (0.32) nmol.l-1] 
confirming the inhibition of ovulation. Serum growth hormone concentrations for 
the NM increased with the onset of running and were not different between 
menstrual cycle phases [main effect time P<0.05; Table 4a], but tended to be 
higher for the OC during days 15-28 [main effect trial P=0.05, main effect time 
P<0.01; Table 4b]. However, the concentrations were not different between the 
groups.  
Table 4 
Metabolic Responses 
For the NM both plasma lactate and ammonia responses did not differ between 
menstrual cycle phases, (main effect time P<0.01, Table 5). Similarly for the OC 
plasma lactate and ammonia did not differ between days 1-14 and 15-28 (main 
effect time P<0.01, Table 5). For the NM plasma glucose concentrations were 
unaffected by menstrual phase [NM FT End: 9.6 (1.2) vs LT End 8.3 (0.9) 
mmol.l-1; main effect time P<0.01]. For the OC plasma glucose concentration 
was higher during days 1-14 than days 15-28 (main effect trial P<0.05, main 
effect time P<0.01; Fig. 2). 
Table 5 
Fig. 2 
Plasma volume  
Estimated resting plasma volume was not different between the FT and LT for 
the NM [FT: 62.2 (1.1) vs LT: 61.9 (1.3) ml.100ml-1]. However resting plasma 
volume for the OC was higher during the days 15-28 than 1-14, [1-14: 61.0 (1.1) 
vs. 15-28: 63.4 (1.3) ml.100ml-1; P<0.05]. There were no differences in resting 
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plasma volume between the groups. The estimated change in plasma volume for 
the NM and OC groups was not different between trials. The decreases in plasma 
volume were not different between the two groups. 
Discussion 
The main finding in the present study was that in unacclimatised women, who 
were eumennorheic, performance, in terms of distance run of prolonged 
intermittent high-intensity running was not significantly affected by the cyclic 
variations in hormones associated with normal menstrual function, whereas for 
oral contraceptive users performance was improved during days 15-28 when 
taking exogenous synthetic hormones compared to days 1-14. For the 
eumennorheic group maximal sprint performance over 15 m, rectal temperature, 
plasma lactate, ammonia and glucose concentrations and serum growth hormone 
concentrations were also not different between the follicular and luteal phases of 
the menstrual cycle. However, for the oral contraceptive users plasma glucose 
concentration was higher and serum growth hormone concentrations were lower 
in days 1-14 in comparison with days 15-28.  
 
The finding of the present study that the performance, rectal temperature, heart 
rate and perceived exertion of unacclimatised eumennorheic women during 
intermittent running in the heat (31 ± 0.2 oC; 23.1 ± 0.9% RH) were unaffected 
by menstrual cycle phase is largely consistent with previous research examining 
other modes of exercise (Wells and Horvath 1974; Horvath and Drinkwater 
1982). During walking in three different environments (28, 35 and 48oC) during 
the flow (follicular), ovulatory and luteal phases no differences in heart rate, deep 
body temperature, sweat rate or performance of the 50 min walk were observed 
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between the three phases (Horvath and Drinkwater 1982). In contrast in 
acclimatised eumennorheic subjects cycling (30% V
.
O2) in the heat (48oC, 10% 
RH), rectal temperature was lower in the follicular in comparison with the luteal 
phase (Carpenter and Nunneley 1988) in good agreement with the well-
documented effect of progesterone on basal body temperature. Similarly during 
cycling at night (70% V
.
O2 max) (when the largest differences in deep body 
temperature between the luteal and follicular phase are observed) in moderate 
environmental conditions after a 4 h rest period in the heat, rectal temperature, 
heart rate, sweating thresholds and oxygen uptake were all lower during the 
follicular in comparison with the luteal phase (Hessemer and Brück 1985). Thus, 
in the present study, while the similar running performance in the follicular and 
luteal phases of the cycle is entirely consistent with previous cycling and walking 
studies, the lack of any effect on deep body temperature or cardiovascular 
responses may be explained by the unacclimatised status of the subjects and the 
intense nature of the exercise.  
 
One exception to the consistency with previous literature in the present study is 
the lack of any difference in rectal temperature between menstrual phases for the 
eumennorheic women prior to the onset of exercise. This may possibly be due to 
the intervening variables associated with travelling to the laboratory and the long 
preparation period (Wells and Horvath, 1973). The similar basal deep body 
temperatures between menstrual phases emphasises the need for a prolonged 
period of passive rest prior to the onset of exercise, to prevent the masking of the 
differences in deep body temperature associated with the follicular and luteal 
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phases of the cycle.  
 
For the oral contraceptive users, performance was improved during days 15-28 
compared to days 1-14.  No previous study has examined performance per se 
during exercise in the heat in oral contraceptive users. However, during cycling 
for 1 h at 60% 2OV& max in the heat (30oC, 50% RH) rectal temperature and heart 
rate were greater when subjects were taking oral contraceptives in comparison 
with a contraceptive free week, which the authors suggested might result in 
reduced capacity or performance in oral contraceptive users (Martin and Buono 
1997). Similarly, Rogers and Baker (1997) recorded a higher rectal temperature 
and heart rate when taking the contraceptive pill compared with the no pill week 
during treadmill walking (22oC, 39% RH). In the current study rectal temperature 
was 0.1oC higher during days 15-28, whereas in the studies comparing pill use 
with the pill free week temperatures were 0.3oC higher (Martin and Buono 1997; 
Rogers and Baker 1997). Martin and Buono (1997) postulated that the high rectal 
temperature may diminish performance, however in the current study 
performance was actually improved. The difference of only 0.1oC clearly 
therefore did not have a negative effect on performance.  
 
There was a higher plasma glucose concentration during the high intensity 
intermittent running during days 1-14 in comparison with days 15-28 in the 
present study, for the oral contraceptive group. Previous studies examining 
glucose concentration, and oral contraceptive use have yielded equivocal 
findings with increases, decreases and no change in glucose concentrations being 
recorded (Bonen et al. 1991; Kanaley et al. 1992; Bemben 1993; Galliven et al. 
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1997; Bailey et al. 2000). These ambivalent findings might be related to the 
intensity and type of exercise, the type of oral contraceptive, the time during the 
contraceptive month and whether the subjects are fasted. When the metabolic 
contribution required from gluconeogenesis is high there tends to be a higher 
glucose concentration for oral contraceptive users during the contraceptive free 
week or when compared to eumennorheic women (Lavoie et al. 1987; Bonen et 
al. 1991; Bemben 1993). During prolonged exercise, blood glucose is initially 
supplied from the breakdown of glycogen and as exercise progresses 
gluconeogenesis becomes more crucial. In the current study, the differences in 
glucose concentrations became greater towards the end of the exercise period. 
Thus, the lower glucose concentration during days 15-28 may be related to the 
higher exogenous ovarian hormones that may impair hepatic gluconeogenesis 
(Lavoie et al. 1987). The lower glucose response could also be due to a decrease 
in hepatic glucose output or an enhanced glucose uptake, utilisation and glycogen 
storage that has been shown with estrogen treatment in animals (Bemben 1993). 
Furthermore, oral contraceptives have been suggested to alter the secretion of 
glucoregulatory hormones and to decrease insulin sensitivity that suppresses 
gluconeogenesis as insulin concentrations have been shown not to differ (Bonen 
et al. 1991; Bemben 1993). 
 
Growth hormone was higher during second 14 day period for the oral 
contraceptive users. Growth hormone has been reported to be higher both at rest 
and during exercise when taking oral contraceptives compared to the 
contraceptive free week and to eumennorheic women (Bonen et al. 1991; 
Bemben et al. 1992; Bemben 1993). This enhanced growth hormone response 
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may be due to estrogen stimulation or could be due to the lower glucose 
concentrations stimulating hypothalamic glucoreceptors (Bemben et al. 1992). 
Growth hormone is associated with an enhanced lipolytic effect and thus has a 
glucose sparing effect (Bak et al. 1991; Moller et al. 1991), which may improve 
performance during prolonged exercise (Bemben et al. 1992; Bemben 1993). 
Total carbohydrate utilisation during 90 min of treadmill exercise (50% 
2OV& max) was lower in women taking oral contraceptives than women in the 
luteal phase of the cycle and this was suggested to be related to the higher growth 
hormone response in this group (Bemben et al. 1992). Thus in the present study 
the improved performance may be related to a glycogen sparing effect, however 
as free fatty acids, insulin and glucagon were not measured, this clearly requires 
further study.  
 
A possible explanation for the improved performance during days 15-28 for the 
OC users is an enhanced running economy. Giacomoni and Falgairette (2000) 
compared responses to a 12 min submaximal treadmill run when off OC (days 2-
4), early on OC use (days 7-9) and late on OC use (days 19-21). Oxygen uptake 
was lower during early and late OC use compared to off OC and running 
economy was improved in late OC use compared to off OC. It was postulated 
that this may be related to biomechanical factors rather than any alteration in 
substrate utilisation. Furthermore, Lynch and Nimmo (1998) observed a higher 
blood lactate and ammonia response to high intensity intermittent running within 
1 week of taking the OC compared with 1 week later. Though this did not impact 
upon performance, it clearly emphasises the differences in metabolism that may 
occur within 1 contraceptive cycle. 
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 The only difference between the groups was a higher resting rectal temperature 
in the OC group than in the eumennorheic group. The progestin concentration in 
the oral contraceptives was high (>150 μg) and therefore the increase in basal 
body temperature, in line with progestin concentration, was not of a gradual 
nature as seen in the menstrual cycle, where progesterone is only produced 
during the luteal phase of the cycle, or in multiphasic oral contraceptive 
preparations, where progestins are only added during the second 14 days (second 
phase) of the cycle. Furthermore the potency of exogenous progestins has been 
shown to be greater than their endogenous counterparts (Bemben 1993). Thus 
exogenous progestins have a significant effect upon thermoregulation (Grucza et 
al. 1993; Rogers and Baker 1997). Both the high progestin concentration and 
potency of the oral contraceptives seem the likely explanation for the higher 
resting rectal temperatures observed.  
 
The protocol employed in the present study was designed to allow comparison 
between groups primarily and as such the lack of specificity of the OC cycle is a 
major limitation. For example, some of the participants would have been taking 
OC for 1-2 days after the week off during the days 1-14 trial. This time has 
previously been associated with a feeling of nausea and may have diminished 
performance. However, taking account of the limitations in protocol design, there 
are clearly some important differences in terms of performance, and some 
possible mechanisms for these differences that require further investigation. 
Research needs to be undertaken during several specific time periods during the 
oral contraceptive month, which incorporates measurement of growth hormone, 
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glucoregulatory hormones, glucose and free fatty acids. 
 
In summary, menstrual cycle phase did not affect performance in terms of 
distance run or 15 m maximal sprint time during prolonged intermittent high 
intensity shuttle running in the heat. However, performance was improved during 
days 15-28 compared to days 1-14 of the contraceptive month. This improvement 
in performance may be related to a glycogen sparing effect or a biomechanical 
improvement though this remains to be elucidated.  
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Table 1 The type and active ingredients of the oral contraceptives. 
Oral contraceptive No. Synthetic estrogens Synthetic progesterones 
Microgynon® 30  5 30 μg ethinylestradiol 150 μg levonorgestrel 
Ovranette® 1 30 μg ethinylestradiol 250 μg levonorgestrel 
Loestrin® 1 20 μg ethinylestradiol 1 mg norethisterone acetate 
Dianette® 1 35 μg ethinylestradiol 2 mg cyproterone acetate 
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Table 2a Rectal temperatures (oC) for the NM during the follicular and luteal 
trials; t = main effect time P<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FT LT 
Subject 
No. 
Rest Post 
Warm 
up 
Set 1 End Rest Post 
Warm 
up 
Set 2 End 
1 37.3 37.65 39.1 39.5 37.0 37.3 39.2 39.8 
2 37.0 37.5 38.9 39.8 37.1 37.15 38.6 39.9 
3 37.3 37.5 38.7 38.9 37.2 37.2 38.5 38.8 
4 37.3 37.6 39.3 39.6 37.4 37.75 39.2 39.45 
5 36.8 36.9 38 39.6 37.0 37.1 38.1 39.5 
6 37.0 37.4 38.7 39.7 37.25 37.6 38.6 39.0 
7 37.1
5 
37.45 38.8 39.4 37.4 37.7 38.8 39.8 
Mean 37.1 37.4 38.8 39.5 37.2 37.4 38.7 39.5 
SE 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.2 
 t 
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Table 2b Rectal temperatures (oC) for the OC during the days 1-14 and 15-28 
trials; T = main effect trial P<0.01; t = main effect time P<0.01. 
 
 Days 1-14 Days 15-28 
Subject 
No. 
Rest Post 
Warm 
up 
Set 1 End Rest Post 
Warm 
up 
Set 2 End 
8 37.3 37.4 38.4 39.0 37.4 37.6 38.6 39.3 
9 37.25 37.4 38.95 39.7 37.5 37.7 38.9 39.7 
10 37.5 37.9 39.1 39.0 37.45 37.7 39.0 39.1 
11 37.2 37.2 38.0 39.4 37.4 37.4 38.4 39.0 
12 37.3 37.65 38.5 38.8 37.35 37.6 38.5 39.4 
13 37.25 37.6 38.9 39.4 37.3 37.7 38.9 39.4 
14 37.6 37.8 38.9 39.75 37.6 37.9 39.1 39.75 
15 37.1 37.1 38.6 39.3 37.3 37.3 38.45 39.2 
Mean 37.3 37.5 38.7 39.3 37.4 37.6 38.7 39.4 
SE 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 
 T, t 
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Table 3a RPE for the NM during the first set and exhaustion sets of the LIST; t = 
main effect time P<0.01. 
 FT LT 
Subject No. Set 1 End Set Set 1 End set 
1 12 20 12 15 
2 10 13 11 17 
3 13 19 15 19 
4 13 17 14 20 
5 12 15 12 19 
6 16 19 17 20 
7 13 17 11 19 
Mean  13 17 13 18 
SE 1 1 1 1 
 t 
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Table 3b RPE for the OC during the first set and exhaustion sets of the LIST; t = 
main effect time P<0.01. 
 1-14 15-28 
Subject No. Set 1 End Set Set 1 End set 
8 15 18 14 19 
9 15 15 13 13 
10 16 20 15 20 
11 12 19 11 19 
12 11 15 11 17 
13 12 12 15 19 
14 16 19 15 19 
15 13 20 13 17 
Mean  14 17 13 18 
SE 1 1 1 1 
 t 
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Table 4a Growth hormone concentration (nmol.l-1) for NM during the first set, 
second set and exhaustion sets of the LIST; t = main effect time P<0.05. 
Subject  FT LT 
No. Rest Set 1 Set 2 End Rest Set 1 Set 2 End 
1 1.1 4.2 3.0 3.0 2.5 8.0 11.0 11.0 
2 10.1 21.2 17.5 10.1 21.6 31.8 25.5 24.9 
3 34.8 37.4 35.0 21.9 28.9 34.5 34.1 14.3 
4 5.2 27.8 25.5 19.4 8.6 41.4 32.4 32.4 
5 30.5 32.7 20.1 17.3 25.8 26.1 20.7 26.1 
6 0.9 26.6 28.9 26.4 2.9 44.0 36.1 36.1 
Mean 13.8 25.0 21.7 16.4 15.1 31.0 26.7 24.1 
SE 6.2 4.7 4.5 3.5 4.8 5.3 3.9 4.0 
 t 
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Table 4b Growth hormone concentration (nmol.l-1) for OC during the first set, 
second set and exhaustion sets of the LIST; T = main effect trial P = 0.05; t = 
main effect time P<0.01. 
Subject Days 1-14 Days 15-28 
No. Rest Set 1 Set 2 End Rest Set 1 Set 2 End 
8 18.5 38.3 24.1 14.2 22.0 41.5 25.8 13.8 
9 34.2 44.1 37.5 35.2 41.3 54.3 43.5 39.3 
10 13.4 30.4 25.7 25.7 9.5 41.3 36.7 36.7 
11 6.9 24.9 20.0 8.2 17.7 49.4 22.9 4.5 
12 43.5 45.0 43.7 31.2 59.4 78.6 72.6 48.9 
13 4.0 32.8 37.8 31.3 15.5 68.3 58.0 61.2 
14 5.6 27.4 17.5 13.2 0.4 11.6 13.5 17.3 
Mean 18.0 34.7 29.5 22.7 23.7 49.3 39.0 31.7 
SE 5.8 3.0 3.8 4.0 7.6 8.2 7.9 7.7 
 T, t 
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Table 5 Plasma lactate and ammonia concentrations for NM and OC at rest and 
exhaustion; t = main effect time P<0.01. 
 Plasma lactate (mmol.l-1) Plasma ammonia (μmol.l-1) 
 Rest End Rest End 
NM     
FT 1.14 ± 0.12 5.26 ± 0.72 16.0 ± 4.0 45.6 ± 8.0 
LT 0.92 ± 0.08 5.40 ± 0.92 13.5 ± 2.2 56.5 ± 10.8 
 t t 
OC     
1-14 1.16 ± 0.15 5.74 ± 0.82 20.7 ± 5.1 42.0 ± 10.2 
15-28 1.13 ± 0.12 5.83 ± 0.97 17.1 ± 5.9 49.9 ± 6.5 
 t t 
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Legends 
Fig. 1 Maximal 15m sprint times during the Loughborough Intermittent Shuttle 
Test (LIST); t = main effect time P<0.05.  
Blank columns for the first set of running for the 4 different groups of subjects. 
Dashed columns for the results obtained during the exhaustion set for the same 4 
groups of subjects. NM FT: group of women with normal menstrual cycles, 
during their follicular phase. NM LT: group of women with normal menstrual 
cycles, during their luteal phase. OC 1-14: group of women on oral 
contraceptives, during the first 14 days of the substitutive cycle. OC 15-28: group 
of women on oral contraceptives, during the second 14 days of the substitutive 
cycle.  
 
Fig. 2 Plasma glucose concentrations for the OC during the days 1-14 and 15-28 
trials; T = main effect trial P<0.05; t = main effect time P<0.01. 
Solid line with triangle: group of women on oral contraceptives, during days 1-
14 of the substitutive cycle. Dashed line with cross: group of women on oral 
contraceptives, during the days 15-28 of the substitutive cycle. 
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